1. Home
  2. FUNC vs IKT Comparison

FUNC vs IKT Comparison

Compare FUNC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First United Corporation

FUNC

First United Corporation

SELL

Current Price

$43.81

Market Cap

282.0M

Sector

Finance

ML Signal

SELL

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.86

Market Cap

274.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUNC
IKT
Founded
1900
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.0M
274.9M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
FUNC
IKT
Price
$43.81
$1.86
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
★ $50.00
$6.00
AVG Volume (30 Days)
27.9K
★ 542.5K
Earning Date
10-23-2026
11-13-2026
Dividend Yield
★ 2.60%
N/A
EPS Growth
19.68
★ 57.76
EPS
★ 1.90
N/A
Revenue
★ $18,426,000.00
N/A
Revenue This Year
$9.57
N/A
Revenue Next Year
$6.10
$33.33
P/E Ratio
$22.84
★ N/A
Revenue Growth
★ 4.01
N/A
52 Week Low
$33.54
$1.33
52 Week High
$46.30
$2.61

Technical Indicators

Market Signals
Indicator
FUNC
IKT
Relative Strength Index (RSI) 50.32 30.76
Support Level $43.30 $1.59
Resistance Level $45.71 $1.91
Average True Range (ATR) 1.12 0.10
MACD 0.02 -0.02
Stochastic Oscillator 45.13 1.04

Price Performance

Historical Comparison
FUNC
IKT

About FUNC First United Corporation

First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: